Trump reportedly plans to announce new drug pricing deals with nearly a dozen drugmakers

Nearly a dozen drugmakers are set to sign voluntary deals with President Trump on Monday to sell outpatient drugs at lower prices tied to cheaper foreign levels. The White House is leveraging its “most favored nation” framework—revived via a May 2025 executive order—potentially giving participating firms exemptions from Medicare discount pilot programs, while Medicaid participation remains optional. With U.S. drug prices reported at ~3x (branded >4x) overseas, the move is likely to pressure near-term pharma revenue and commercial strategy as companies also invest billions to expand U.S. manufacturing to mitigate tariff risks.

Analysis

This is more a valuation-tax event than an immediate earnings event. Because Medicaid already sits deep in the rebate stack, the incremental cash hit is likely smaller than the headline suggests; the bigger near-term effect is that investors will keep a political discount on U.S.-heavy branded pharma until the scope is clarified and state opt-in data shows real uptake.

The market is likely to punish the highest-expectation growth franchises first: LLY and NVO carry more policy beta because their long-duration growth narratives depend on premium U.S. pricing and clean margin expansion. PFE is less exposed to obesity-specific pricing optics, but it is not immune; the issue is the sector multiple, not just one line item, and the U.S. pricing debate can compress forward EV/EBITDA across pharma if it becomes a recurring election-cycle headline.

Over 1-3 months, the key catalyst is whether this stays an optional Medicaid accommodation or turns into a broader Medicare/tariff enforcement path. Over 6-18 months, the real second-order effect is capital allocation: more U.S. manufacturing capex, more direct-to-consumer spend, and potentially slower margin recovery if companies keep trading price concessions for regulatory relief. The contrarian view is that the move may be overdone if participation is narrow; if states barely opt in and the administration stops at negotiated discounts, the market may quickly re-rate the event as mostly symbolic.

Key Decisions for Investors

• Use any relief rally in LLY/NVO to initiate 1-3 month put spreads rather than outright shorts; the trade is against multiple compression from policy overhang, with downside limited if the announcement proves cosmetic. Falsify if the White House clearly limits the program to a small set of optional Medicaid states and excludes Medicare follow-through.
• Relative value: short NVO vs long PFE on a 4-8 week horizon. The risk/reward is that NVO’s higher policy sensitivity and richer growth multiple should underperform if the market starts pricing a broader U.S. price reset, while PFE is less exposed to the headline growth-to-margin narrative.
• Do not chase the first headline unless state opt-in language is explicit. Set a watch item for the next 2-4 weeks: if participation is weak or implementation is delayed, cover any tactical pharma shorts because the event will likely fade into a negotiation framework rather than a P&L shock.
• If the announcement mentions Medicare or tariff linkage, add to sector hedges via XBI/IBB puts as a cleaner expression than single-name shorts. That would signal the policy is migrating from symbolic pricing optics to a broader earnings-risk regime.